Futura Medical PLC
LSE:FUM

Watchlist Manager
Futura Medical PLC Logo
Futura Medical PLC
LSE:FUM
Watchlist
Price: 32 GBX 0.16% Market Closed
Market Cap: 97.2m GBX
Have any thoughts about
Futura Medical PLC?
Write Note

Operating Margin
Futura Medical PLC

-49.8%
Current
-89%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-49.8%
=
Operating Profit
-4.2m
/
Revenue
8.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
UK
Futura Medical PLC
LSE:FUM
95.7m GBP
-50%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
743.6B USD
35%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
346B USD
28%
US
Merck & Co Inc
NYSE:MRK
248.8B USD
34%
CH
Roche Holding AG
SIX:ROG
199.5B CHF
32%
UK
AstraZeneca PLC
LSE:AZN
161.6B GBP
21%
CH
Novartis AG
SIX:NOVN
171.3B CHF
31%
US
Pfizer Inc
NYSE:PFE
149.2B USD
22%
Country UK
Market Cap 95.7m GBP
Operating Margin
-50%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 743.6B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.7T DKK
Operating Margin
44%
Country US
Market Cap 346B USD
Operating Margin
28%
Country US
Market Cap 248.8B USD
Operating Margin
34%
Country CH
Market Cap 199.5B CHF
Operating Margin
32%
Country UK
Market Cap 161.6B GBP
Operating Margin
21%
Country CH
Market Cap 171.3B CHF
Operating Margin
31%
Country US
Market Cap 149.2B USD
Operating Margin
22%
No Stocks Found

Futura Medical PLC
Glance View

Market Cap
95.7m GBX
Industry
Pharmaceuticals

Futura Medical Plc is a pharmaceutical group that develops products for both the prescription and consumer healthcare markets. The company is headquartered in Guildford, Surrey and currently employs 13 full-time employees. The company went IPO on 2006-07-10. The firm is focused on developing a portfolio of products based on its transdermal DermaSys technology. Its patented transdermal DermaSys technology provides rapid and targeted local delivery of medical treatments via the skin. The firm is engaged in developing a portfolio of products for therapeutic areas, such as sexual health, including erectile dysfunction, and pain relief. The firm's products include MED3000 and TPR100. The firm's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The firm has conducted a Phase III study using MED3000 in ED. TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.

FUM Intrinsic Value
15.77 GBX
Overvaluation 51%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-49.8%
=
Operating Profit
-4.2m
/
Revenue
8.4m
What is the Operating Margin of Futura Medical PLC?

Based on Futura Medical PLC's most recent financial statements, the company has Operating Margin of -49.8%.